Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: It is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study

Annals of Oncology

Volumn 17, Issue SUPPL. 7, 2006, Pages

  Agnese, V ^a   Corsale, S ^a   Calo V ^a   Augello, C ^a   Bruno, L ^a   Calcara, D ^a   Crosta, A ^a   Rodolico, V ^a   Rinaldi, G ^a   Cicero, G ^a   Latteri, F ^b   Agrusa, A ^a   Morello, V ^a   Adamo, V ^a   Altavilla, G ^c   Di Fede, G ^a   Fiorentino, E ^b   Grassi, N ^b   Latteri, M A ^b   Valerio, M R ^a   Tomasino, R M ^a   Colucci, G ^d   Bazan, V ^a   Russo, A ^a   more..

^a UNIVERSITY OF PALERMO   (Italy)

^b Section of Surgical Oncology   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Colorectal cancer; Laryngeal squamous cell carcinoma; P16 hypermethylation; Salivary gland cancer

Indexed keywords

GENOMIC DNA; PROTEIN P16INK4A;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RELAPSE; CLINICAL FEATURE; COLORECTAL CANCER; DNA EXTRACTION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN METHYLATION; SALIVARY GLAND TUMOR; SQUAMOUS CELL CARCINOMA; UNIVARIATE ANALYSIS; CANCER STAGING; COLORECTAL TUMOR; DNA METHYLATION; GENETICS; HEAD AND NECK TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; COLORECTAL NEOPLASMS; DNA METHYLATION; GENES, P16; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PROMOTER REGIONS (GENETICS);

EID: 33745610076     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl967     Document Type: Article

References (36)

1. Fruhwald MC. DNA methylation patterns in cancer: Novel prognostic indicators? Am J Pharmacogenomics 2003; 3: 245-260.
2. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003; 4: 351-358.
3. Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol 2000;15: 835-842.
4. Costello JF, Fruhwald MC, Smiraglia DJ at al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 132-138.
5. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
6. Sun Y, Deng D, You WC et al. Methylation of p16 CpG islands associated with malignant transformation of gastric dysplasia in a population-based study. Clin Cancer Res 2004; 10: 5087-5093.
7. Nadal A, Cardesa A. Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch 2003; 442(1): 1-7.
8. Giordano A, Macaluso M. Prognostic significance of pRb family and p16(INK4) alterations in colorectal cancer: An interesting point of view in a complex net of molecular signals. Hum Pathol 2004; 35: 1171-1172.
9. Cui X, Shirai Y, Wakai T et al. Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 2004; 35: 1189-1195.
10. Gonzalez-Quevedo R, Garcia-Aranda C, Moran A et al. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: Clinical implications. Int J Oncol 2004; 24: 349-355.
11. Norrie MW, Hawkins NJ, Todd AV et al. Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol 2003; 84: 143-145.
12. Lee S, Hwang KS, Lee HJ et al. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 2004; 84: 884-893.
13. Riese U, Dahse R, Fiedler W et al. Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Int J Mol Med 1999; 4: 61-65.
14. Puri SK, Si L, Fan CY, Hanna E. Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am J Otolaryngol 2005; 26: 12-17.
15. Jares P, Nadal A, Fernandez PL et al. Disregulation of p16MTS1/CDK4I protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx. Int J Cancer 1999; 81: 705-711.
16. El-Naggar AK, Lai S, Clayman G et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997; 151: 1767-1774.
17. Lo KW, Cheung ST, Leung SF et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996; 56: 2721-2725.
18. Smigiel R, Sasiadek M, Krecicki T et al. Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx. Mol Carcinog 2004; 39: 147-154.
19. MTS1/CDK41 mutation and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene 1997; 18: 1444-1453.
20. Merlo A, Herman JG, Mao L et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ GDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
21. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16: 1197-1206.
22. Ruas M, Peters G. The p16INK4a/CDKN2a tumor suppressor and its relatives. Bioch Bioph Acta 1998; 1378: 115-177.
23. Weber A, Langhanki L, Schutz A et al. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland. J Pathol 2002; 198: 326-334.
24. Davis CD, Uthus EO. DNA methylation, cancer susceptibility and nutrient interactions. Exp Biol Med 2004; 229: 988-995.
25. Nishimine M, Nakamura M, Kishi M et al. Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. Oncol Rep 2003; 10: 555-560.
26. Li J, El-Naggar A, Mao L. Promoter methylation of p16(INK4a), RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 2005; 104: 771-776.
27. Burri N, Shaw P, Bouzourene H et al. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 2001;81(3): 217-29.
28. Hawkins N, Norrie M, Cheong K et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002; 122: 1376-1387.
29. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-5442.
30. Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4230.
31. Guan RJ, Fu Y, Holt PR, Pardee AB. Association of K-ras mutations with p16 methylation in human colon cancer. Gastroenterology 1999; 116: 1063-1071.
32. Liang JT, Chang KJ, Chen JC et al. Hypermethylation of the p16 gene in sporadic T3NOMO stage colorectal cancers:aSsociation with DNA replication error and shorter survival. Oncology 1999; 57: 149-156.
33. Wiencke JK, Zheng S, Lafuente A et al. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 501-506.
34. Sanz-Casla MT, Maestro ML, Vidaurreta M et al. p16 Gene methylation in colorectal tumors: Correlation with clinicopathological features and prognostic value. Dig Dis 2005; 23: 151-155.
35. Liang JT, Chang KJ, Chen JC et al. Hypermethylation of the p16 gene in sporadic T3NOMO stage colorectal cancers: Association with DNA replication error and shorter survival. Oncology 1999; 57: 149-156.
36. Maeda K, Kawakami K, Ishida Y et al. Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep 2003; 10: 935-938.